Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 12, Number 10—October 2006

Research

Active Surveillance of Candidemia, Australia

Sharon Chen*Comments to Author , Monica Slavin†, Quoc Nguyen‡, Deborah Marriott‡, E. Geoffrey Playford§, David Ellis¶, Tania Sorrell*#, and the Australian Candidemia Study
Author affiliations: *Westmead Hospital, Westmead, New South Wales, Australia; †Royal Melbourne Hospital, Melbourne, Victoria, Australia; ‡St. Vincent's Hospital, Sydney, New South Wales, Australia; §Princess Alexandra Hospital, Brisbane, Queensland, Australia; ¶Women's and Children's Hospital, Adelaide, South Australia, Australia; #University of Sydney, Sydney, New South Wales, Australia

Main Article

Table 4

Multivariate predictors of death by candidemia 30 days after diagnosis, Australia, 2001–2004*

Characteristic OR 95% CI p value
Age >65 y 3.0 2.0–4.3 <0.001
ICU stay 3.2 2.1–5.0 <0.001
Corticosteroid therapy 2.8 1.9–4.1 <0.001
Hemodialysis 2.4 1.4–4.1 0.002
Hyperalimentation 1.7 1.1–2.5 0.006
Antimicrobial drug use 2.1 0.9–4.4 0.07
Neutropenia 2.2 1.3–3.6 0.002
Sepsis present 3.1 1.7–5.4 <0.001
Treatment with antifungal agent 0.01 0.06–0.2 <0.001
Candida glabrata infection 1.8 1.1–2.9 0.01

*Sixteen candidate variables were included in the final model. OR, odds ratio; CI, confidence interval; ICU, intensive care unit.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO